|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A23400961]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2006.12.01)(ÇöÀç¾à°¡)
\6 ¿ø/1Á¤(2005.08.08)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»ö¿øÇü´çÀÇÁ¤
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
500DRG |
| ¾à¸®ÀÛ¿ë |
[Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
- À§±Ë¾çÄ¡·á º¸Á¶
- ¿¬Ã༺´ëÀå¿°¡¤¿¬Ã༺¹æ±¤¡¤¹æ±¤¿°¡¤À¯¹®¿¬Ãࡤº¹ºÎ°æ·Ã¿¡¼ÀÇ ¿îµ¿Ç×Áø Á¶Àý, À§»êºÐºñ Á¶Àý, ³»Àå°æ·Ã Á¶Àý
- ±â´ÉÀû Àå Àå¾Ö(°æ¹ÌÇÑ ÀÌÁú, °Ô½Ç¿°, ±Þ¼º ´ëÀå¿°)ÀÇ Áõ»ó ¿ÏÈ
- °ú¹Î¼º´ëÀåÁõÈıº(°ú¹Î¼º ´ëÀå, °æ·Ã¼º ´ëÀå, Á¡¾×¼º °áÀå¿°) ¹× ±â´ÉÀû À§Àå°üÀå¾ÖÀÇ Ä¡·á º¸Á¶
- ¸ð¸£ÇÉ ¶Ç´Â ±âŸÀÇ ¸¶¾à°ú º´¿ëÇÏ¿© ½Å»êÅë ¹× ´ã³¶»êÅëÀÇ Áõ»ó °æ°¨
- ÆÄŲ½¼Áõ¿¡¼ °Á÷¡¤ÁøÀüÀÇ °æ°¨ ¹× Ÿ¾×ºÐºñ¡¤´ÙÇÑÁõÀÇ Á¶Àý
- Ç×Äݸ°¿¡½ºÅ×¶óÁ¦ ¾à¹° Áßµ¶ óġ
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Hyoscyamine]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:172501ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
Ȳ»êÈ÷¿ä½º½Ã¾Æ¹ÎÀ¸·Î¼ 1ȸ 0.125-0.25mg 1ÀÏ 3-4ȸ °æ±¸Åõ¿©ÇÑ´Ù. ¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
³ì³»Àå ȯÀÚ, Æó»ö¼º ºñ´¢±â Áúȯ(Àü¸³¼± ºñ´ë¿¡ ÀÇÇÑ ¹æ±¤°æºÎ Æó»ö) ȯÀÚ, À¯¹®½ÊÀÌÁöÀå ÇùÂø µî À§Àå°ü Æó»ö ȯÀÚ, ¸¶ºñ¼º ÀåÆó»ö ȯÀÚ, °í·ÉÀÚ ¶Ç´Â ¼è¾àȯÀÚÀÇ ¸¶ºñ¼º Àå ¹«±äÀåÁõ, ±Þ¼º ÃâÇ÷ÀÇ ºÒ¾ÈÁ¤ÇÑ ½ÉÇ÷°ü ȯÀÚ, ÁßÁõÀÇ ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ, °Å´ë °áÀå ȯÀÚ, ÁßÁõ ±Ù¹«·ÂÁõ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
±¸°¥, ¹è´¢°ï¶õ, ¿äÆó»ö, ½Ã¾ß¸ù·Õ, ½É°èÇ×Áø, µ¿°ø»ê´ë, ¸ð¾ç±Ù ¸¶ºñ, ¾È¾ÐÁõ°¡, µÎÅë, ½Å°æÅë, ¾îÁö·¯¿ò, À¯ÁóºÐºñ¾ïÁ¦, µÎµå·¯±â µîÀÇ ÇǺÎÁúȯ, ¹ßÇÑ °¨¼Ò, °ú·®º¹¿ë½Ã µÎÅë, ±¸Åä, ½Ã¾ß¸ù·Õ, µ¿°ø»ê´ë, ¹ß¿, ÇǺΰÇÁ¶, Á¹À½, ±¸°¥, ¿¬Çϰï¶õÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. |
| ÀÌ»ó¹ÝÀÀ |
±¸°¥, ¹è´¢°ï¶õ, ¿äÆó»ö, ½Ã¾ß¸ù·Õ, ½É°èÇ×Áø, µ¿°ø»ê´ë, ¸ð¾ç±Ù ¸¶ºñ, ¾È¾ÐÁõ°¡, µÎÅë, ½Å°æÅë, ¾îÁö·¯¿ò, À¯ÁóºÐºñ¾ïÁ¦, µÎµå·¯±â µîÀÇ ÇǺÎÁúȯ, ¹ßÇÑ °¨¼Ò, °ú·®º¹¿ë½Ã µÎÅë, ±¸Åä, ½Ã¾ß¸ù·Õ, µ¿°ø»ê´ë, ¹ß¿, ÇǺΰÇÁ¶, Á¹À½, ±¸°¥, ¿¬Çϰï¶õÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| ÀϹÝÀû ÁÖÀÇ |
¾îÁö·¯¿ò, ½Ã¾ß¸ù·ÕÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î º»Á¦¸¦ Åõ¿©ÁßÀΠȯÀÚ´Â ÀÚµ¿Â÷¿îÀü µî À§ÇèÀÌ ¼ö¹ÝµÇ´Â ±â°èÁ¶ÀÛÀ» ÇÏÁö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù. |
| »óÈ£ÀÛ¿ë |
- Ç×¹«½ºÄ«¸° ¾à¹°, ¾Æ¸¸Å¸µò, MAOÀúÇØÁ¦, »ïȯ°è Ç׿ì¿ï¾à, Ç×È÷½ºÅ¸¹ÎÁ¦, Æä³ëÄ¡¾ÆÁø°è ¾à¹°, ÇÒ·ÎÆä¸®µ¹°ú º´¿ë½Ã º»Á¦ÀÇ ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù
- Á¦»êÁ¦´Â º»Á¦ÀÇ Èí¼ö¸¦ ÀúÇØÇϹǷΠº´¿ë½Ã º»Á¦´Â ½ÄÀü¿¡ Åõ¿©Çϰí Á¦»êÁ¦´Â ½ÄÈÄ¿¡ Åõ¿©ÇÑ´Ù.
|
| ÀӺο¡ ´ëÇÑ Åõ¿© |
[ÀӺαݱ⠼ººÐ Á¶È¸]
žƵ¶¼º ¹× ÀӽŴɷ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â °¡ÀӺο¡´Â Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù
|
| ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© |
º»Á¦´Â ¸ðÀ¯ÁßÀ¸·Î ÀÌÇàµÇ¹Ç·Î º»Á¦ÀÇ Åõ¿©Áß¿¡´Â ¼öÀ¯¸¦ Áß´ÜÇÑ´Ù. |
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(hyoscyamine; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Hyoscyamine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Hyoscyamine competes favorably with acetylcholine for binding at muscarinic receptors in the salivary, bronchial, and sweat glands as well as in the eye, heart, and gastrointestinal tract. The actions of hyoscyamine result in a reduction in salivary, bronchial, gastric and sweat gland secretions, mydriasis, cycloplegia, change in heart rate, contraction of the bladder detrusor muscle and of the gastrointestinal smooth muscle, and decreased gastrointestinal motility.
|
| Pharmacology |
Hyoscyamine¿¡ ´ëÇÑ Pharmacology Á¤º¸ L-Hyoscyamine, the active optical isomer of atropine (dl-hyoscyamine), is a tertiary amine anticholinergic gastrointestinal agent.
|
| Protein Binding |
Hyoscyamine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 50%
|
| Half-life |
Hyoscyamine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 2-3.5 hours
|
| Absorption |
Hyoscyamine¿¡ ´ëÇÑ Absorption Á¤º¸ Absorbed totally and completely by sublingual administration as well as oral administration.
|
| Pharmacokinetics |
Hyoscyamine SulfateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : 2-3ºÐ
- ÀÛ¿ëÁö¼Ó½Ã°£ : 4-6½Ã°£
- Èí¼ö : °æ±¸ : Èí¼ö ÀßµÊ
- ºÐÆ÷ : ÅÂ¹Ý Åë°ú, À¯Áó¿¡ ¼Ò·® ºÐÆ÷
- ´Ü¹é°áÇÕ : 50%
- ´ë»ç : °£´ë»ç
- ¹Ý°¨±â : 3.5½Ã°£(¹æÃâÁ¦¾îÇü : 7½Ã°£)
- ¼Ò½Ç : ½Å¹è¼³
- Ç÷¾×Åõ¼®°ú º¹¸·Åõ¼®À¸·Î Á¦°ÅµÊ
|
| Biotransformation |
Hyoscyamine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
|
| Toxicity |
Hyoscyamine¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation. LD50=mg/kg(orally in rat)
|
| Drug Interactions |
Hyoscyamine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Donepezil Possible antagonism of actionGalantamine Possible antagonism of actionRivastigmine Possible antagonism of actionHaloperidol The anticholinergic increases the risk of psychosis and tardive dyskinesia
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Hyoscyamine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take 30 minutes before meals, and at bedtime.
|
| Drug Target |
[Drug Target]
|
| Description |
Hyoscyamine¿¡ ´ëÇÑ Description Á¤º¸ Hyoscyamine is a chemical compound, a tropane alkaloid it is the levo-isomer to atropine. It is a secondary metabolite of some plants, particularly henbane (Hyoscamus niger.)Hyoscyamine is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, pancreatitis, colic and cystitis. It has also been used to relieve some heart problems, control some of the symptoms of Parkinson's disease, as well as for control of respiratory secretions in end of life care.
|
| Dosage Form |
Hyoscyamine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Solution / drops OralTablet Oral
|
| Drug Category |
Hyoscyamine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adjuvants, AnesthesiaAnti-Arrhythmia AgentsAntiarrhythmic AgentsAntimuscarinicsAntispasmodicsBronchodilator AgentsMuscarinic AntagonistsMydriaticsParasympatholytics
|
| Smiles String Canonical |
Hyoscyamine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1C2CCC1CC(C2)OC(=O)C(CO)C1=CC=CC=C1
|
| Smiles String Isomeric |
Hyoscyamine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1[C@H]2CC[C@@H]1C[C@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
|
| InChI Identifier |
Hyoscyamine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13?,14?,15?,16-/m1/s1
|
| Chemical IUPAC Name |
Hyoscyamine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) (2S)-3-hydroxy-2-phenylpropanoate
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2016-05-10
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|